Santhera Pharmaceuticals has announced the nomination of Dr. Srishti Gupta as an Independent Director, set to be voted on at their upcoming Annual General Meeting on May 26, 2026. Dr. Gupta brings over 20 years of experience in the biopharmaceutical industry, including her recent role as CEO of Idorsia Pharmaceuticals, where she successfully led a turnaround that significantly increased the company’s revenues and market capitalization. Her extensive background in both the medical field and strategic consulting positions her to contribute valuable insights as Santhera continues to expand its reach and improve access to its innovative treatments, particularly AGAMREE®, a new medication for Duchenne muscular dystrophy.

This appointment is particularly relevant for individuals interested in advancements in treatments for rare diseases. AGAMREE® has been approved in several regions, including the U.S. and Europe, as a novel alternative to traditional corticosteroids for managing Duchenne muscular dystrophy, a condition that affects muscle strength and function. The involvement of experienced leaders like Dr. Gupta could enhance the development and availability of such treatments, potentially benefiting families affected by this condition.

The announcement comes as Santhera is poised for growth, with Dr. Gupta’s expertise expected to guide the company through its next phase. While the nomination is a positive step, it’s important to note that this is an early-stage development within the company, and the full impact of Dr. Gupta’s leadership will take time to unfold. For those following advancements in pharmaceutical care, this could signal promising changes in the landscape of treatment options for neuromuscular diseases.

Source: globenewswire.com